Danaher (NYSE:DHR)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Credit Suisse Group in a report released on Friday.
Several other research analysts also recently commented on the company. Deutsche Bank lowered their target price on Danaher from $114.00 to $107.00 and set a “buy” rating for the company in a research note on Thursday, March 1st. Barclays assumed coverage on Danaher in a research note on Thursday, February 15th. They set an “overweight” rating and a $110.00 target price for the company. Argus upped their price objective on Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada reaffirmed a “hold” rating and issued a $98.00 price objective on shares of Danaher in a research note on Wednesday, January 31st. Finally, Stifel Nicolaus upped their price objective on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $101.40.
Shares of Danaher (NYSE:DHR) traded up $0.45 during midday trading on Friday, reaching $103.25. The company’s stock had a trading volume of 93,486 shares, compared to its average volume of 2,631,811. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The firm has a market capitalization of $72,128.68, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 2.17 and a beta of 1.03. Danaher has a 12-month low of $78.97 and a 12-month high of $104.82.
In related news, insider Rainer Blair sold 51,080 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $97.26, for a total value of $4,968,040.80. Following the sale, the insider now directly owns 50,477 shares in the company, valued at $4,909,393.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the completion of the sale, the executive vice president now owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders sold 313,260 shares of company stock worth $31,657,786 over the last quarter. 12.20% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. increased its holdings in Danaher by 276.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock worth $225,332,000 after purchasing an additional 1,929,751 shares during the period. BlackRock Inc. increased its position in shares of Danaher by 4.6% during the fourth quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after acquiring an additional 1,789,474 shares during the period. Findlay Park Partners LLP increased its position in shares of Danaher by 52.9% during the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after acquiring an additional 1,425,000 shares during the period. JPMorgan Chase & Co. increased its position in shares of Danaher by 86.1% during the third quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock worth $256,136,000 after acquiring an additional 1,393,165 shares during the period. Finally, Evercore Trust Company N.A. purchased a new stake in shares of Danaher during the third quarter worth $113,606,000. Hedge funds and other institutional investors own 77.83% of the company’s stock.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.